Skip to main content
CSL
  • Global Selector
  • Newsroom
  • Partnering
  • Contact
  • We Are CSL
    We Are CSL
    Our Businesses and Products
    Vita: Original Stories
    Our Leadership
    Worldwide Locations
    Corporate Governance
    Our Businesses and Products
    CSL Behring
    CSL Seqirus
    CSL Vifor
    Corporate Governance
    Code of Responsible Business Practice
    Core Policies

    Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.

    Read the Stories

    CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.

    Our Businesses and Products
  • Patients & Public Health
    Patients & Public Health
    Rare & Serious Diseases
    Iron Deficiency
    Nephrology
    Vaccines
    Patient Support & Organizations
    Rare & Serious Diseases
    Immunodeficiency and Autoimmune Diseases
    Hereditary Bleeding Disorders
    Hereditary Angioedema
    Alpha 1 Antitrypsin Deficiency
    Iron Deficiency
    Iron Deficiency Patient Stories
    Nephrology
    Nephrology Patient Stories
    Vaccines
    COVID-19
    Pandemic Response
    In-Licensing
    Antivenoms and Q fever Vaccine
    Patient Support & Organizations
    CSL Behring USA Support & Assistance Programs
    CSL Vifor Managed Access Programs
    LEAD Grants
    CSL Community Impact Awards

    Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.

    CSL Behring: Rare & Serious Diseases

    Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.

    CSL Seqirus: Vaccines
  • R&D
    R&D
    R&D Capabilities
    Awards, Grants and Initiatives
    World-Class R&D Network
    Product Pipeline
    Clinical Studies at CSL
    Clinical Studies at CSL
    Current Clinical Trials
    Research Practices
    How to Participate
    Clinical Studies FAQs

    R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.

    R&D Capabilities

    One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.

    Awards, Grants and Initiatives
  • Sustainability
    Sustainability
    Healthier Environment
    Healthier Communities
    Promising Futures
    Governance
    Data and Reporting Centre
    Healthier Environment
    Climate Resilience
    Energy
    Water and Waste
    Healthier Communities
    Product Safety & Quality
    Innovation and R&D
    Access and Affordability
    Responsible & Resilient Supply Chain
    Donor Experience
    Patient Experience
    Promising Futures
    Talent and Culture
    Health, Safety & Wellbeing
    Inclusion and Belonging
    Governance
    Ethics & Transparency
    Data Protection & Privacy
    Stakeholder Engagement & Material Topics
    Data and Reporting Centre
    Annual Publications
    Policies
    Key Performance Data Summary

    As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.

    Learn About Our Targets

    Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.

    Supporting Our Communities
  • Careers
    Careers
    Inclusion and Belonging
    How CSL Supports Your Well-being
    Early Careers at CSL
    Early Careers at CSL
    Apprenticeships
    Internships at CSL
    Graduate Rotational Programs at CSL

    At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.

    Read About Our Approach to Inclusion and Belonging

    Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!

    Early Careers at CSL
  • Investors
CSL

  • We Are CSL
    • We Are CSL
    • Our Businesses and Products
      • Our Businesses and Products
      • CSL Behring
      • CSL Seqirus
      • CSL Vifor
    • Vita: Original Stories
    • Our Leadership
    • Worldwide Locations
    • Corporate Governance
      • Corporate Governance
      • Code of Responsible Business Practice
      • Core Policies
  • Patients & Public Health
    • Patients & Public Health
    • Rare & Serious Diseases
      • Rare & Serious Diseases
      • Immunodeficiency and Autoimmune Diseases
      • Hereditary Bleeding Disorders
      • Hereditary Angioedema
      • Alpha 1 Antitrypsin Deficiency
    • Iron Deficiency
      • Iron Deficiency
      • Iron Deficiency Patient Stories
    • Nephrology
      • Nephrology
      • Nephrology Patient Stories
    • Vaccines
      • Vaccines
      • COVID-19
      • Pandemic Response
      • In-Licensing
      • Antivenoms and Q fever Vaccine
    • Patient Support & Organizations
      • Patient Support & Organizations
      • CSL Behring USA Support & Assistance Programs
      • CSL Vifor Managed Access Programs
      • LEAD Grants
      • CSL Community Impact Awards
  • R&D
    • R&D
    • R&D Capabilities
    • Awards, Grants and Initiatives
    • World-Class R&D Network
    • Product Pipeline
    • Clinical Studies at CSL
      • Clinical Studies at CSL
      • Current Clinical Trials
      • Research Practices
      • How to Participate
      • Clinical Studies FAQs
  • Sustainability
    • Sustainability
    • Healthier Environment
      • Healthier Environment
      • Climate Resilience
      • Energy
      • Water and Waste
    • Healthier Communities
      • Healthier Communities
      • Product Safety & Quality
      • Innovation and R&D
      • Access and Affordability
      • Responsible & Resilient Supply Chain
      • Donor Experience
      • Patient Experience
    • Promising Futures
      • Promising Futures
      • Talent and Culture
      • Health, Safety & Wellbeing
      • Inclusion and Belonging
    • Governance
      • Governance
      • Ethics & Transparency
      • Data Protection & Privacy
      • Stakeholder Engagement & Material Topics
    • Data and Reporting Centre
      • Data and Reporting Centre
      • Annual Publications
      • Policies
      • Key Performance Data Summary
  • Careers
    • Careers
    • Inclusion and Belonging
    • How CSL Supports Your Well-being
    • Early Careers at CSL
      • Early Careers at CSL
      • Apprenticeships
      • Internships at CSL
      • Graduate Rotational Programs at CSL
  • Investors
  • Newsroom
  • Partnering
  • Contact
  • Global Selector

Did you know? CSL is investigating a potential treatment to improve the health of people living with end-stage kidney disease (ESKD). 

ESKD patients face an increased risk of cardiac events, like heart attacks and strokes.

Learn More From Patients

CSL's 2025 Half Year Financial Results Click here for Full Information including Webcast Recording →   |    Would you like to read our 2024 Annual Report? Click here to view or download the Annual Report →

CSL
CSL Behring
CSL Seqirus
CSL Vifor

CSL. Always Evolving for a Better World.

CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.

Our Businesses and Products

CSL Behring. Leading the Way in Treating Rare and Serious Diseases.

CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.

More About CSL Behring

CSL Seqirus. Global Vaccine Leader.

Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.

More About CSL Seqirus

CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.

The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.

More About CSL Vifor
CSL Logo The text 'CSL' in bold white all capitals.
CSL Behring Logo The text 'CSL Behring' in bold white.
CSL Seqirus Logo The text 'CSL Seqirus' in bold white.
CSL Vifor Logo The text 'CSL Vifor' in bold white.
CSL Logo

CSL. Always Evolving for a Better World.

CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.

Our Businesses and Products
CSL Behring Logo

CSL Behring. Leading the Way in Treating Rare and Serious Diseases.

CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.

More About CSL Behring
CSL Seqirus Logo

CSL Seqirus. Global Vaccine Leader.

Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.

More About CSL Seqirus
CSL Vifor Logo

CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.

The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.

More About CSL Vifor

Vita: Original Stories

'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.

Participants in the CSL-sponsored Hackathon at Drexel University

CSL Supported Hackathons at Three Universities

CSL sponsored recent hackathon events that attracted students to find creative solutions to business problems.

22 May 2025
Vickie, a participant in a clinical trial for end-stage kidney disease (ESKD)

Video: Kidney Disease Patients in a Clinical Trial

Did you know? CSL is investigating a potential treatment to improve the health of people living with end-stage kidney disease…

19 May 2025
A globe with blood vessels being held by two hands - International Vasculitis Day is 15 May

See the Winning Logo: International Vasculitis Day

CSL Vifor supported the initiative, which invited patients to choose a visual identity designed to raise awareness and unite …

15 May 2025
CSL scientist in Switzerland

Careers at CSL

We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?

Pictured: CSL employees in Melbourne, Australia

Promising Futures at CSL

CSL on LinkedIn

Follow us!
LinkedIn
22 May

Meet Reagan Bender, who has thrived at CSL for 11 years! Starting in sales, Reagan's career has evolved through various roles, showcasing CSL's supportive and collaborative environment. By leveraging mentorship and thinking ahead, Reagan has grown within the organization and made a meaningful impact on patient lives. Discover how CSL can be the perfect place for your professional growth. https://bit.ly/4dDdts8 #CSLCareers #CareerGrowth #Mentorship #GreatPlaceToWork #JoinCSL #PromisingFutures

LinkedIn
22 May

Some symptoms you can see. Others stay hidden—and hit harder. Life doesn’t stop when you're diagnosed with ANCA-Associated Vasculitis \(AAV\). But everything quietly shifts. The disease rarely shows on the outside, yet it reaches into every corner of a person’s life. Yes, the body is affected—joint pain, fatigue, or physical changes that may be visible. But what truly defines the experience of living with AAV often lies beneath the surface. A promising career might be paused indefinitely. The plans, routines, and relationships that once felt solid begin to feel fragile. Even simple joys become difficult to hold onto when your body is in constant survival mode. The emotional weight is real—and often underestimated. There’s the fear of losing independence, the pressure of financial instability, the strain it can place on the people you love most, on a relationship with a partner. AAV affect how people see themselves, how they relate to others, how they envision their future. AAV doesn’t just attack the body—it attacks one’s sense of identity, stability, and purpose. That’s the side of AAV we don’t talk about enough. And that’s the side we’re here to acknowledge today. At CSL, we believe raising awareness means seeing the full picture. Not just the medical symptoms, but the human experience behind them. Because living with AAV is more than managing inflammation—it's managing life. Join us in supporting all those whose battles may be invisible, but never insignificant. Learn more on https://bit.ly/43s07Ki #AAVAwareness #LifeWithAAV

LinkedInPostImage
LinkedIn
21 May

At CSL, sustainability isn’t just a buzzword. It’s embedded in everything we do across the globe. We’re committed to reducing emissions, rethinking resources and designing facilities that support a healthier, more sustainable future. #PromisingFutures #CSL Reinvent the world with us: https://bit.ly/4kxW7z9

LinkedInPostImage
LinkedIn
20 May

Vickie, who is living with end-stage kidney disease, is participating in a clinical trial and encourages researchers to keep looking for answers. Today is #ClinicalTrialsDay https://bit.ly/43jMjSc

LinkedIn
19 May

On Friday, CSL celebrated 15 years as the major sponsor of BioMelbourne Network 's annual ‘Connecting Women’ luncheon. This year's event was particularly special due to its theme, 'Driving Women's Health Forward,' focusing on a topic close to our hearts - the prevention of Cervical Cancer. With over 600 attendees, we were privileged to hear from A/Prof Misha Coleman (Australian Centre for the Prevention of Cervical Cancer ) and Kerrie Castor on how self-collection testing, vaccination, and other preventative measures are helping pave the way for Australia to become the first country in the world to eliminate cervical cancer by 2035. Pictured: CSL’s Devon Anderson, HR Executive Director and CSL colleagues in attendance at the luncheon. #biomelbwomen #womeninstem

LinkedIn
19 May

CSL is delighted to announce the appointment of Mary Oates as the new Chief Operating Officer. In this pivotal role, Mary will lead CSL’s enterprise Operations organization, encompassing manufacturing, quality, supply chain, technical operations, and network strategy. Mary brings a wealth of leadership expertise spanning more than 25 years in the biopharmaceutical industry. We extend our warmest welcome to Mary and look forward to the impact she will make. Click here to learn more about our leadership: https://bit.ly/3SeDdkF #CSL #Leadership #DrivenByOurPromise

LinkedInPostImage
LinkedIn
16 May

On #HAEDay , we’re proud to unite with the hereditary angioedema \(#HAE \) community in raising awareness of this rare and debilitating genetic disease. Our commitment to advancing treatments for HAE remains steadfast. Our ultimate goal is to improve the quality of life for people like Arianna, who courageously navigate the day-to-day fear of experiencing a painful and potentially life-threatening swelling attack. Together, we can drive innovation and work towards a future where those affected by HAE can live without fear of attacks. Read more of Arianna’s experience with HAE and her hopes for the future of HAE treatment: https://lnkd.in/eT9XUEjU #CSL

LinkedIn
15 May

🌎 Today, on International Vasculitis Day \(IVD\), we are happy to celebrate a major step forward in raising global awareness for vasculitis: the introduction of the first-ever official logo for IVD. This new visual identity, developed by Vasculitis International and chosen by the global patient community, marks a significant milestone in amplifying the visibility of this rare and complex group of diseases — and we are proud to have supported this important initiative. See the logo here https://lnkd.in/eVus29X3 At CSL, we understand that living with ANCA-Associated Vasculitis \(AAV\), a type of rare and severe vasculitis, is about far more than managing a medical condition. It’s about navigating a journey marked by uncertainty and challenges — many of which remain invisible. That’s why our commitment goes beyond developing treatments. We believe true innovation is only possible when we walk alongside patients and truly listen to their voices. Through initiatives like the Vasculitis Together, and hand-in-hand with patients, advocates, and partners worldwide, we are driving forward progress — because behind every innovation, there is a human story that matters. On this important day, we invite you to hear directly from AAV patients Catherine and Shanali — voices that inspire all of us in CSL to push forward. Today, we reaffirm our promise: We see you. We hear you. We stand with you. Learn more on AAV https://lnkd.in/eM5Tn-8C #VasculitisDay #AAVAwareness #HolisticCare #LifeWithAAV #IVD2025

LinkedIn
14 May

Today, on IgAN Awareness Day, we stand with everyone affected by IgA nephropathy — a rare, chronic kidney disease that can ultimately lead to kidney failure. Also known as Berger’s disease, IgAN impacts approximately 2.5 in 100,000 people per year worldwide. Its early symptoms are often subtle or absent, which means many live with the condition for years before receiving a diagnosis. While it can affect anyone, IgAN is most commonly diagnosed in young adults between their teens and late 30s — often just as they're planning their futures. At CSL, we are deeply committed to making a meaningful difference for people living with IgAN. We are proud our innovative treatment for IgAN has been converted from conditional to standard marketing approval in the European Union — a major step forward that will offer new hope to more patients and their families across Europe. But innovation doesn’t stop at treatment. Through initiatives like My Kidney House https://bit.ly/3GSDkjv, we provide patients and caregivers with reliable, easy-to-understand resources to help them better navigate their healthcare journey. Awareness matters. Early diagnosis matters. Innovation matters. And at CSL, we’ll continue to advance science and amplify support — because every person living with IgAN deserves to be seen, heard, and helped. Learn more about how IgAN impacts the kidneys by watching our short explainer video here https://bit.ly/44C34ug? #IgANAwarenessDay #KidneyHealth #KidneyDisease #MyKidneyHouse #CSL

LinkedIn
13 May

Tomorrow’s medical breakthroughs start today. At CSL, research is about making discoveries that lead to impact. Join a team dedicated to shaping the future of medicine. #PromisingFutures #CSL Explore opportunities: https://bit.ly/44w86bC

We Are CSL

  • Our Businesses and Products
  • Vita: Original Stories
  • Our Leadership
  • Worldwide Locations
  • Corporate Governance

Patients & Public Health

  • Rare & Serious Diseases
  • Iron Deficiency
  • Nephrology
  • Vaccines
  • Patient Support & Organizations

R&D

  • R&D Capabilities
  • Awards, Grants and Initiatives
  • World-Class R&D Network
  • Product Pipeline
  • Clinical Studies at CSL

Sustainability

  • Healthier Environment
  • Healthier Communities
  • Promising Futures
  • Governance
  • Data and Reporting Centre

Careers

  • Inclusion and Belonging
  • How CSL Supports Your Well-being
  • Early Careers at CSL

Investors

Terms of Use Cookie Policy Global Privacy Policy Accessibility Statement Sitemap
  • Terms of Use
  • Cookie Policy
  • Global Privacy Policy
  • Accessibility Statement
  • Sitemap
CSL logo

CSL, All Rights Reserved © 2025

  • Instagram

CSL
  • CSL (CSL Behring's Parent Company)
CSL Behring Worldwide

Americas

  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Mexico

Asia Pacific

  • Australia
  • China
  • Japan
  • Korea
  • Singapore
  • Taiwan

Middle East

  • Saudi Arabia
  • United Arab Emirates (MEA)

Europe

  • Austria
  • Belgium and Luxembourg
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Italy
  • Netherlands
  • Norway
  • Poland
  • Slovakia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
CSL Plasma (CSL Behring Subsidiary)
  • CSL Plasma US
  • CSL Plasma Germany
  • CSL Plasma Hungary